文献速递肾癌与肾肿瘤

ACCURATE试验方案:三维影像引导机器人辅助肾部分切除术治疗复杂性肾肿瘤的随机对照研究

Clinical Trial Protocol for ACCURATE: A CCafU-UroCCR Randomized Trial: Three-dimensional Image-guided Robot-assisted Partial Nephrectomy for Renal Complex Tumor (UroCCR 99).
PubMed 文献 · Eur Urol Oncol · 2025-04-07

ACCURATE是一项在法国14个中心开展的前瞻性、1:1随机、单盲3期优效性研究,计划36个月内入组694例复杂肾肿瘤患者,比较三维影像引导机器人辅助肾部分切除术与标准机器人手术的疗效。主要终点为复合三项指标(切缘阴性、无并发症、术后1个月eGFR保留>90%),数据通过UroCCR数据库收集,采用逻辑回归分析主要终点。

要点

  • 研究比较3D影像引导与标准机器人辅助肾部分切除术的复合三项指标。
  • 主要终点包含切缘阴性、无并发症及术后1个月eGFR>90%。
  • 计划入组694例,随机1:1,单盲,随访36个月。

核心结论

  • 该试验旨在评估三维影像引导机器人辅助肾部分切除术是否优于标准机器人手术,以改善手术精确性和肾功能保留。

研究设计与样本

  • 前瞻性、1:1随机、单盲、3期优效性研究,在法国肾癌研究网络14个中心开展,计划36个月入组694例患者。

主要发现

  • 原文未报告研究结果,仅描述研究设计与终点。

关键数值与推荐

  • 主要终点为复合三项指标:切缘阴性、无并发症、术后1个月eGFR>90%。
  • 次要终点包括肿瘤学结局、中转开放率、围手术期参数和经济评价。
  • 数据通过UroCCR数据库收集,主要终点采用逻辑回归分析,次要终点采用多种回归方法。

临床怎么用

  • 若试验证实优效,三维影像引导技术可能成为复杂肾肿瘤肾部分切除术的新标准。

局限性

  • 外科医生对三维技术的经验存在差异,技术采纳存在后勤挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Renal cancer often requires nephron-sparing surgery for optimal patient outcomes. Despite advances in imaging and robot-assisted surgery, there is a need to enhance surgical precision and renal preservation. This trial evaluates the effectiveness of three-dimensional image-guided robot-assisted partial nephrectomy versus standard methods in improving surgical outcomes. CLINICAL TRIAL DESIGN AND TIMEFRAME: This trial is a prospective, 1:1 randomized, single-blind phase 3 superiority study conducted across 14 centers within the French Network for Research on Kidney Cancer, aiming to enroll 694 patients over 36 mo. ENDPOINTS: The primary endpoint is a composite trifecta score, including negative surgical margins, no complications, and renal function preservation (estimated glomerular filtration rate >90% at 1 mo). The secondary endpoints include oncological outcomes, conversion rates, perioperative parameters, and economic evaluation. DATA SOURCES AND STATISTICAL ANALYSIS PLAN: Data are collected via the UroCCR database. Logistic regression will analyze the primary endpoint, and various regression methods will address the secondary outcomes. Economic evaluations involve incremental cost-utility and cost-effectiveness ratios. STRENGTHS AND LIMITATIONS: Strengths include the multicenter design and robust randomization. Limitations involve variability in surgeons' experience with the new three-dimensional technology and logistical challenges in technology adoption. PATIENT SUMMARY: This clinical trial is designed to evaluate a new surgical technique for treating kidney tumors called three-dimensional (3D) image-guided robot-assisted partial nephrectomy. This study aims to determine whether this new method is more effective and safer than the current standard robot-assisted surgery by improving surgical precision and preserving kidney function. Kidney tumors require precise surgical removal to ensure the best outcomes for patients both during and after surgery. While robotic assistance has improved many surgeries, use of advanced 3D imaging during these procedures might enhance the surgeon's ability to operate with greater accuracy, potentially leading to better patient outcomes and fewer complications. Participants in the trial will undergo surgery using either the conventional robotic-assisted method or the new 3D image-guided technique. The method used for each participant will remain undisclosed to maintain the study's integrity. All participants will receive the highest standard of care, and their progress will be monitored closely throughout the trial. This study hopes to demonstrate that the 3D image-guided method can improve surgical precision and outcomes for patients undergoing kidney tumor removal. If successful, this technique could set a new standard for kidney surgery and improve the overall care patients receive in the future. The addition of 3D reconstruction to the surgery carries very little extra risk. If any technical issues occur, the surgeons can switch back to the regular method without affecting safety. The 3D technology we use, Synapse 3D, is approved and used in hospitals worldwide, ensuring that its safety is well proven by existing evidence.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Margue G, Bernhard JC, Giai J, et al. Clinical Trial Protocol for ACCURATE: A CCafU-UroCCR Randomized Trial: Three-dimensional Image-guided Robot-assisted Partial Nephrectomy for Renal Complex Tumor (UroCCR 99). Eur Urol Oncol. 2025. PMID: 40199643. doi:10.1016/j.euo.2025.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。